Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor‐related cutaneous adverse events with outcomes in metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor‐related cutaneous adverse events with outcomes in metastatic renal cell carcinoma

Published:2021-04-19 Issue: Volume: Page:
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatol

Author:

Corona‐Rodarte Eduardo¹,Olivas‐Martínez Antonio¹²,Remolina‐Bonilla Yuly A.³,Domínguez‐Cherit Judith G.⁴,Lam Elaine T.⁵,Bourlon Maria T.³

Affiliation:

1. Department of Internal Medicine Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico

2. Department of Biostatistics University of Washington Seattle WA USA

3. Department of Hematology and Oncology Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico

4. Department of Dermatology Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico

5. Division of Medical Oncology Department of Medicine University of Colorado Anschutz Medical Campus Aurora CO USA

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.15583

Reference25 articles.

1. Cancer statistics, 2020

2. International Agency for Research on Cancer.Global Cancer Observatory: Cancer Today.2018.

3. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

4. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma

5. Impact of sunitinib‐induced hypothyroidism on survival of patients with metastatic renal cancer;Vasileiadis T;BMC Cancer,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report;Immunotherapy;2022-12

2. Skin manifestations associated with checkpoint inhibitors;JEADV Clinical Practice;2022-05-10